r 1000 cuvettes (MaxCyte Inc)
MaxCyte Inc is a verified supplier 
MaxCyte Inc manufactures this product 
93
Structured Review
MaxCyte Inc
r 1000 cuvettes
R 1000 Cuvettes, supplied by MaxCyte Inc, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/r+1000+cuvettes/R-1000/bio_rxiv__64898__2026__02__27__708432-80-7-10
Average 93 stars, based on 10 article reviews
R 1000 Cuvettes, supplied by MaxCyte Inc, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/r+1000+cuvettes/R-1000/bio_rxiv__64898__2026__02__27__708432-80-7-10
Average 93 stars, based on 10 article reviews
r 1000 cuvettes - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
other:Article Title: Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells: Potency despite risk of translocations Article Snippet: An Isolation:Article Title: High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Article Snippet: 1Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.. 2Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.. 3Department of Medicine, University of California San Francisco, San Francisco, CA, USA. Article Title: Hybrid ssDNA repair templates enable high yield genome engineering in primary cells for disease modeling and cell therapy manufacturing Article Snippet: Encouragingly, Genscript templates encoding a BCMA-CAR knock-in were able to be manufactured at large scale and consistently outperformed our internally generated HDRTs, showing lower levels of toxicity and higher knock-in efficiencies for both ssCTS and dsCTS constructs ( ). .. To demonstrate a large-scale non-viral CAR T manufacturing process, ~100 x 10 6 primary human T cells were isolated from two healthy donors, activated on Day 0 with CD3/CD28 Dynabeads along with IL-7 and IL-15, electroporated on Day 2 using |